This approach is currently being tested in clinical trials with LY260636824 in BRCA1/2 mutation associated breast or ovarian cancer, triple negative breast cancer, high grade serous ovarian cancer, metastatic castrate-resistant prostate cancer, small cell lung cancer, and paediatric solid CNS tumours. This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.